Junshi Biosciences Licenses Roconkibart to Fosun Wanbang for Greater China
Event summary
- Junshi Biosciences licenses roconkibart (anti-IL-17A) to Fosun Wanbang for Greater China, including mainland China, Hong Kong, Macao, and Taiwan.
- Deal includes RMB215 million upfront payment, up to RMB1.125 billion in milestones, and double-digit royalties on net sales.
- Roconkibart showed 91% PASI 90 response rate at week 16 in Phase 3 psoriasis trials; NDA accepted by China's NMPA in December 2025.
The big picture
This deal underscores the growing collaboration between Chinese biotech innovators and established pharma players to address unmet needs in autoimmune diseases. Fosun Wanbang's commercial expertise complements Junshi Biosciences' R&D strengths, reflecting a broader trend of strategic partnerships in China's rapidly evolving biopharmaceutical sector.
What we're watching
- Commercialization Pace
- How Fosun Wanbang's established commercialization framework will accelerate roconkibart's market entry in Greater China.
- Regulatory Progress
- The timeline for NMPA approval and potential expansion into other autoimmune indications beyond psoriasis.
- Revenue Impact
- Whether milestone payments and royalties will materially boost Junshi Biosciences' financials in the near term.
Related topics